Current progress in the treatment of chronic hepatitis C

Table 1 New agents against hepatitis C virus currently evaluated in phase II or III trials

Drug	Company
NS3/4A protease inhibitors
First generation, linear
Boceprevir (Approved)	MERCK
Telaprevir (Approved)	JANSSEN
Narlaprevir	MERCK
First generation, macrocyclic
BI201335	BOEHRINGER Ingelheim
TMC435	TIBOTEC/JANSSEN
Danoprevir	ROCHE
Vaniprevir	MERCK
Asunaprevir	BRISTOL-MYERS SQUIBB
ABT-450	ABBOTT
GS-9451	GILEAD
GS-9256	GILEAD
ACH-1625	ACHILLION
Second generation, macrocyclic
MK-5172	MERCK
Nucleos(t)ide analogue inhibitors of HCV polymerase
PSI/GS-7977	PHARMASSET/GILEAD
Mericitabine	ROCHE
IDX-184	IDENIX
Non-nucleoside analogue inhibitors of HCV polymerase
Tegobuvir	GILEAD
Filibuvir	PFIZER
ANA-598/Setrobuvir	ANADYS/ROCHE
BI207127	BOEHRINGER Ingelheim
ABT-333	ABBOTT
ABT-072	ABBOTT
VX-222	VERTEX
NS5A inhibitors
Daclatasvir	BRISTOL-MYERS SQUIBB
GS-5885	GILEAD
GSK2336805	GSK
Cyclophilin inhibitors
Alisporivir1	NOVARTIS
SCY-635	Scynexis

¹On hold by the United States Food and Drug Administration because of toxicity (pancreatitis cases with one death). HCV: Hepatitis C virus.

Table 2 Sustained virological response rates in phase III clinical trials with hepatitis C virus protease inhibitor-based regimens in treatment-naïve and treatment-experienced patients

Name of trial		SVR
Naïve patients - Treatment group
SPRINT-2
BOC/RGT		63%
BOC44/PR48		66%
PR48		38%
ADVANCE
T12PR		75%
T8PR		69%
PR		44%
ILLUMINATE
T12PR24 (eRVR+)		92%
T12PR48 (eRVR+)		87%
T12PR48 (eRVR-)		64%
< 20 wk		23%
Treatment-experienced patients - Treatment group
RESPOND-2
Prior relapsers	PR48	29%
	BOC/RGT	69%
	BOC44/PR48	75%
Prior partial responders	PR48	7%
	BOC/RGT	40%
	BOC44/PR48	52%
REALIZE
Prior relapsers	PR48	24%
	LIT12PR48	88%
	T12PR48	83%
Prior partial responders	PR48	15%
	LIT12PR48	54%
	T12PR48	59%
Prior null responders	PR48	5%
	LIT12PR48	33%
	T12PR48	29%

BOC: Boceprevir; RGT: Response-guided therapy; P: Pegylated interferon-alfa; R: Ribavirin; T: Telaprevir; eRVR: Extended rapid virological response; LI: Lead-in; SVR: Sustained virological response.